Hybrid Imaging by SPECT/CT and PET/CT: Proven Outcomes in Cancer Imaging

Seminars in Nuclear Medicine

Volumn 39, Issue 4, 2009, Pages 276-289

  Bockisch, Andreas ^a   Freudenberg, Lutz S ^a   Schmidt, Daniela ^b   Kuwert, Torsten ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; CAPROMAB PENDETIDE IN 111; CARBON 11; CARCINOEMBRYONIC ANTIGEN; CONTRAST MEDIUM; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GALLIUM CITRATE GA 67; IODINE 124; IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; PENTETREOTIDE IN 111; PHOSPHONIC ACID DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SUCCIMER TC 99M; TECHNETIUM 99M; TETROFOSMIN TC 99M; THALLIUM 201; TRACER;

ARTIFACT; BONE DISEASE; BONE METASTASIS; BREATHING PATTERN; CANCER DIAGNOSIS; CANCER SCINTISCANNING; CANCER STAGING; CARCINOID; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DOSIMETRY; HEAD AND NECK TUMOR; HUMAN; HYBRID IMAGING; IMAGE QUALITY; IMAGING SYSTEM; ISOTOPE LABELING; LUNG CARCINOMA; LYMPH NODE METASTASIS; LYMPHOMA; LYMPHOSCINTIGRAPHY; MEDICAL TECHNOLOGY; MELANOMA; MOLECULAR IMAGING; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; REVIEW; SENTINEL LYMPH NODE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THYROID CANCER; NEOPLASMS; PATHOLOGY; PROCEDURES; RADIOGRAPHY; SCINTISCANNING;

HUMANS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 66049110492     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2009.03.003     Document Type: Review

References (120)

1. Townsend D.W., and Beyer T. A combined PET/CT scanner: The path to true image fusion. Br J Radiol 75 Spec No (2002) S24-S30
2. Warburg O., Wind F., and Neglers E. On the Metabolism of Tumors in the Body (1930), Constable, London 254-270
3. Engel H., Steinert H., Buck A., et al. Whole-body PET: Physiologic and artifactual fluoro-deoxyglucose accumulations. J Nucl Med 37 (1996) 441-446
4. Lindholm P., Minn H., Leskinen-Kallio S., et al. Influence of the blood glucose concentration on FDG uptake in cancer-A PET study. J Nucl Med 34 (1993) 1-6
5. Gambhir S.S., Czernin J., Schwimmer J., et al. A tabulated summary of the FDG PET literature. J Nucl Med 42 Suppl 5 (2001) 1-93
6. Knapp W.H. Leitlinie zur Tumordarstellung mit (F-18)-Fluordeoxyglukose (FDG). Nuklearmedizin 38 (1999) 267-269
7. Reske S.N., and Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 28 (2001) 1707-1723
8. Diederichs C.G., Staib L., Vogel J., et al. Values and limitations of 18F-fluorodeoxyglucosepositronemission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 20 (2000) 109-116
9. Weber W.A., Avril N., and Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol 175 (1999) 356-373
10. Adams S., Baum R.P., Stuckensen T., et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 25 (1998) 1255-1260
11. Buell U., Wieres F.J., Schneider W., et al. 18FDGPET in 733 consecutive patients with or without side-by-side CT evaluation: Analysis of 921 lesions. Nuklearmedizin 43 (2004) 210-216
12. Reinartz P., Wieres F.J., Schneider W., et al. Side-by-side reading of PET and CT scans in oncology: Which patients might profit from integrated PET/CT?. Eur J Nucl Med Mol Imaging 31 (2004) 1456-1461
13. Hutton B.F., and Braun M. Software for image registration: Algorithms, accuracy, efficacy. Semin Nucl Med 33 (2003) 180-192
14. Beyer T., Rosenbaum S., Veit P., et al. Respiration artifacts in whole-body (18)F-FDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1-16 detector rows. Eur J Nucl Med Mol Imaging 32 (2005) 1429-1439
15. Beyer T., Townsend D.W., and Blodgett T.M. Dualmodality PET/CT tomography for clinical oncology. Q J Nucl Med 46 (2002) 24-34
16. Antoch G., Freudenberg L.S., Beyer T., et al. To enhance or not to enhance?. 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med 45 Suppl 1 (2004) 56S-65S
17. Antoch G., Freudenberg L.S., Egelhof T., et al. Focal tracer uptake: A potential artifact in contrast enhanced dual-modality PET/CT scans. J Nucl Med 43 (2002) 1339-1342
18. Antoch G., Stattaus J., Nemat A.T., et al. Non-small-cell lung cancer: Dual-modality PET/CT in preoperative staging. Radiology 229 (2003) 526-533
19. Beyer T., Antoch G., Muller S., et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med 45 Suppl 1 (2004) 25S-35S
20. Goerres G.W., Kamel E., Heidelberg T.N., et al. PET/CT image coregistration in the thorax: Influence of respiration. Eur J Nucl Med Mol Imaging 29 (2002) 351-360
21. Goerres G.W., Burger C., Schwitter M.R., et al. PET/CT of the abdomen: Optimizing the patient breathing pattern. Eur Radiol 13 (2003) 734-739
22. Beyer T., Antoch G., Blodgett T., et al. Dual-modality PET/CT imaging: The effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 30 (2003) 588-596
23. Cohade C., Osman M., Marshall L.N., et al. PETCT: Accuracy of PET and CT spatial registration of lung lesions. Eur J Nucl Med Mol Imaging 30 (2003) 721-726
24. Beyer T., Antoch G., Bockisch A., et al. Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT. J Nucl Med 46 (2005) 429-435
25. Heusner T.A., Fronz U., Jentzen W., et al. The effect of different chemoembolization materials on CT-based attenuation correction in PET/CT. Rofo 179 (2007) 1159-1165
26. Czernin J., Allen-Auerbach M., and Schelbert H.R. Improvements in cancer staging with PET/CT: Literature-based evidence as of September 2006. J Nucl Med 48 (2007) 78S-88S
27. Halpern B.S., Schiepers C., Weber W.A., et al. Presurgical staging of non-small-cell lung cancer: PET and PET/CT in NSCLC positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 128 (2005) 2289-2297
28. Kim J.H., Czernin J., Allen-Auerbach M.S., et al. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 46 (2005) 587-595
29. Feinstein A.R., Sosin D.M., and Wells C.K. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312 (1985) 1604-1608
30. Freudenberg L.S., Pink R., Beyer T., et al. FDG-PET/CT bei Bronchialkarzinomen. Der. Nuklearmediziner 9 (2003) 273-277
31. Chee K.G., Nguyen D.V., Brown M., et al. Positron emission tomography and improved survival in patients with lung cancer: The Will Rogers phenomenon revisited. Arch Intern Med 28 (2008) 1541-1549
32. Freudenberg L.S., Antoch G., Jentzen W., et al. Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 14 (2004) 2092-2098
33. Freudenberg L.S., Antoch G., Frilling A., et al. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: Role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging 35 (2008) 950-977
34. Freudenberg L.S., Jentzen W., Görges R., et al. 124I-PET dosimetry in advanced differentiated thyroid cancer: Therapeutic impact. Nuklearmedizin 46 (2007) 121-128
35. Jentzen W., Freudenberg L., Eising E.G., et al. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. J Nucl Med 49 (2008) 1017-1023
36. Jentzen W., Weise R., Kupferschläger J., et al. Iodine-124 PET dosimetry in differentiated thyroid cancer: Recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging 35 (2008) 611-623
37. Buchmann I., Henze M., Engelbrecht S., et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34 (2007) 1617-1626
38. Buck A.K., Stollfuss J.C., Stahl A., et al. Nuclear medical diagnostics for liver tumors. Internist 48 (2007) 21-24
39. Bouchelouche K., and Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: An update review. J Urol 179 (2008) 34-45
40. Larson S.M., and Schöder H. Advances in positron emission tomography applications for urologic cancers. Curr Opin Urol 18 (2008) 65-70
41. Kotzerke J., Volkmer B.G., Glatting G., et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 42 (2003) 25-30
42. Husarik D.B., Miralbell R., Dubs M., et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 35 (2008) 253-263
43. Rinnab L., Mottaghy F.M., Blumstein N.M., et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100 (2007) 786-793
44. Seo Y., Mari C., and Hasegawa B.H. Technological development and advances in single-photon emission computed tomography/computed tomography. Semin Nucl Med 38 (2008) 77-198
45. O'Connor M.K., and Kemp B.J. Single-photon emission computed tomography/computed tomography: Basic instrumentation and innovations. Semin Nucl Med 36 (2006) 258-266
46. Keidar Z., Israel O., and Krausz Y. SPECT/CT in tumor imaging: Technical aspects and clinical applications. Semin Nucl Med 33 (2003) 205-218
47. Schillaci O. Hybrid SPECT/CT: A new era for SPECT imaging?. Eur J Nucl Med Mol Imaging 32 (2005) 521-524
48. Krausz Y., and Israel O. Single-photon emission computed tomography/computed tomography in endocrinology. Semin Nucl Med 36 (2006) 267-274
49. Schillaci O. Single-photon emission computed tomography/computed tomography in lung cancer and malignant lymphoma. Semin Nucl Med 36 (2006) 275-285
50. Horger M., and Bares R. The role of single-photon emission computed tomography/computed tomography in benign and malignant bone disease. Semin Nucl Med 36 (2006) 286-294
51. Sodie D.B., Sodie A.E., and Bakale G. Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 37 (2007) 17-28
52. Husarik D.B., and Steinert H.C. Single-photon emission computed tomography/computed tomography for sentinel node mapping in breast cancer. Semin Nucl Med 37 (2007) 29-33
53. Schillaci O., Filippi L., Manni C., et al. Single-photon emission computed tomography/computed tomography in brain tumors. Semin Nucl Med 37 (2007) 34-47
54. Mariani G., Flotats A., and Israel O. Clinical Applications of SPECT/CT: New Hybrid Nuclear Medicine Imaging System (2008), International Atomic Energy Agency, Vienna
55. Buck A.K., Nekolla S., Ziegler S., et al. SPECT/CT. J Nucl Med 49 (2008) 1305-1309
56. Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 46 (2005) 1356-1367
57. Love C., Din A.S., Tomas M.B., et al. Radionuclide bone imaging: An illustrative review. Radiographics 23 (2003) 341-358
58. Van den Bosch M.A., Hollingworth W., Kimmonth A.L., et al. Evidence against the use of lumbar spine radiography for low back pain. Clin Radiol 59 (2004) 69-76
59. Horger M., Eschmann S.M., Pfannenberg C., et al. Evaluation of combined transmission and emission tomography for classification of skeletal lesions. AJR 183 (2004) 655-661
60. Römer W., Nömayr A., Uder M., et al. SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med 47 (2006) 1102-1106
61. Utsunomiya D., Shiraishi S., Imuta M., et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: Comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology 238 (2006) 264-271
62. Strobel K., Burger C., Seifert B., et al. Characterization of focal bone lesions in the axial skeleton: Performance of planar bone scintigraphy compared with SPECT and SPECT fused with CT. AJR 188 (2007) W467-W474
63. McDougall I.R. Thyroid Cancer in Clinical Practice (2007), Springer, London
64. Schlumberger M., and Pacini F. Thyroid Tumors. (ed 5) (2003), Éditions Nucléon, Paris 3-317
65. Gimm O., Brauckhoff M., Thanh P.N., et al. An update on thyroid surgery. Eur J Nucl Med Mol Imaging 29 Suppl 2 (2002) S447-S452
66. 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. J Nucl Med 50 (2009) 18-23
67. Shapiro B., Rufini V., Jarwan A., et al. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body I-131 scans in patients with thyroid cancer. Semin Nucl Med 30 (2000) 115-132
68. 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging 31 (2004) 1435-1442
69. Ruf J., Lehmkuhl L., Bertram H., et al. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl Med Commun 25 (2004) 1177-1782
70. 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma. J Nucl Med 49 (2008) 1952-1957
71. Kwekkeboom D.J., and Krenning E.P. Somatostatin receptor imaging. Semin Nucl Med 32 (2002) 84-91
72. Rufini V., Calcagni M.L., and Baum R.P. Imaging of neuroendocrine tumors. Semin Nucl Med 36 (2006) 228-247
73. Perri M., Erba P., Volterrani D., et al. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging 52 (2008) 323-333
74. 111In-pentetreotide in assessment of neuroendocrine tumors. Clin Endocrinol 59 (2003) 565-573
75. Pfannenberg A.C., Eschmann S.M., Horger M., et al. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging 30 (2003) 835-843
76. Hillel P.G., van Beek E.J., Taylor C., et al. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumors. Clin Radiol 61 (2006) 579-587
77. Reubi J.C., and Maecke H.R. Peptide-based probes for cancer imaging. J Nucl Med 49 (2008) 1735-1738
78. 18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: Basic aspects and emerging clinical applications. J Nucl Med 49 (2008) 573-586
79. Ilias I., and Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 89 (2004) 479-491
80. 123I-MIBG scintigraphy. Nuklearmedizin 43 (2004) 164-170
81. 123I-MIBG SPECT/CT. J Nucl Med 47 (2006) 1635-1642
82. Rozovsky K., Koplewitz B.Z., Krausz Y., et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. Am J Roentgenol 190 (2008) 1085-1090
83. Even-Sapir E., Keidar Z., Sachs J., et al. The new technology of combined transmission and emission tomography in evaluating endocrine neoplasms. J Nucl Med 42 (2001) 998-1004
84. Chajari M., Lacroix J., Peny A.M., et al. Gallium-67 scintigraphy in lymphoma: Is there a benefit of image fusion with computed tomography?. Eur J Nucl Med Mol Imaging 29 (2002) 380-387
85. 67Ga-SPECT/CT with a hybrid system in the clinical management of lymphoma. Eur J Nucl Med Mol Imaging 32 (2005) 1011-1017
86. Carrera D., Bajen M.T., Mora J., et al. Clinical utility of fused 67Ga SPECT/CT scan images in patients with lymphoma. Rev Esp Med Nucl 25 (2006) 3-9
87. Filippi L., Schillaci O., Santoni R., et al. Usefulness of SPECT/CT with a hybrid camera for the functional anatomical mapping of primary brain tumors by [Tc 99m] tetrofosmin. Cancer Biother Radiopharm 21 (2006) 41-48
88. Wong T.Z., Turkington T.G., Polascik T.J., et al. ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol 184 (2005) 676-680
89. Schillaci O., Danieli R., Filippi L., et al. Scintimammography with a hybrid SPECT/CT imaging system. Anticancer Res 27 (2007) 557-562
90. Sergiacomi G., Schillaci O., Leporace M., et al. Integrated multislice CT and Tc99m sestamibi SPECT-CT evaluation of solitary pulmonary nodules. Radiol Med 111 (2006) 213-224
91. Luciani A., Itti E., Rahmouni A., et al. Lymph node imaging: Basic principles. Eur J Radiol 58 (2006) 338-344
92. Mariani G., Moresco L., Viale G., et al. Radioguided sentinel lymph node biopsy in breast cancer surgery. J Nucl Med 42 (2001) 1198-1215
93. Mariani G., Gipponi M., Moresco L., et al. Radioguided sentinel lymph node biopsy in malignant cutaneous melanoma. J Nucl Med 43 (2002) 811-827
94. Even-Sapir E., Lerman H., Lievshitz G., et al. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med 44 (2003) 1413-1420
95. Kretschmer L. Dynamic lymphoscintigraphy and image fusion of SPECT and pelvic CT-scans allow mapping of aberrant pelvic sentinel lymph nodes in malignant melanoma. Eur J Cancer 39 (2003) 175-183
96. Lopez R., Payoux P., Gantet P., et al. Multimodal image registration for localization of sentinel nodes in head and neck squamous cell carcinoma. J Oral Maxillofac Surg 62 (2004) 1497-1504
97. Terada A., Hasegawa Y., Goto M., et al. Sentinel lymph node radiolocalization in clinically negative neck oral cancer. Head Neck 28 (2006) 114-120
98. Lerman H., Metser U., Lievshitz G., et al. Lymphoscintigraphic sentinel node identification in patients with breast cancer: The role of SPECT-CT. Eur J Nucl Med Mol Imaging 33 (2006) 329-337
99. Sherif A., Garske U., de la Torre M., et al. Hybrid SPECT-CT: An additional technique for sentinel node detection of patients with invasive bladder cancer. Eur Urol 50 (2006) 83-91
100. Bilde A., von Buchwald C., Mortensen J., et al. The role of SPECT-CT in the lymphoscintigraphic identification of sentinel nodes in patients with oral cancer. Acta Otolaryngol 126 (2006) 1096-1103
101. Keski-Säntti H., Mätzke S., Kauppinen T., et al. Sentinel lymph node mapping using SPECT-CT fusion imaging in patients with oral cavity squamous cell carcinoma. Eur Arch Otorhinolaryngol 263 (2006) 1008-1012
102. Ishihara T., Kaguchi A., Matsushita S., et al. Management of sentinel lymph nodes in malignant skin tumors using dynamic lymphoscintigraphy and the single-photon-emission computed tomography/computed tomography combined system. Int J Clin Oncol 11 (2006) 214-220
103. Khafif A., Schneebaum S., Fliss D.M., et al. Lymphoscintigraphy for sentinel node mapping using a hybrid single photon emission CT (SPECT)/CT system in oral cavity squamous cell carcinoma. Head Neck 28 (2006) 874-879
104. Maza S., Taupitz M., Taymoorian K., et al. Multimodal fusion imaging ensemble for targeted sentinel lymph node management: Initial results of an innovative promising approach for anatomically difficult lymphatic drainage in different tumour entities. Eur J Nucl Med Mol Imaging 34 (2007) 378-383
105. Gallowitsch H.J., Kraschl P., Igerc I., et al. Sentinel node SPECT-CT in breast cancer. Can we expect any additional and clinically relevant information?. Nuklearmedizin 46 (2007) 252-256
106. Nomori H., Ikeda K., Mori T., et al. Sentinel node identification in clinical stage Ia non-small-cell lung cancer by a combined single photon emission computed tomography/computed tomography system. J Thorac Cardiovasc Surg 134 (2007) 182-187
107. Tsujino Y., Kusatake K., Kaneko S., et al. Fusion of single-photon emission computed tomography and computed tomography images of sentinel lymph nodes in extramammary Paget's disease of the scrotum. J Dermatol 34 (2007) 712-715
108. Van der Ploeg I.M., Valdes Olmos R.A., Nieweg O.E., et al. The additional value of SPECT/CT in lymphatic mapping in breast cancer and melanoma. J Nucl Med 48 (2007) 1756-1760
109. Lerman H., Lievshitz G., Zak O., et al. Improved sentinel node identification by SPECT/CT in overweight patients with breast cancer. J Nucl Med 48 (2007) 201-206
110. Beneder C., Fuechsel F.G., Krause T., et al. The role of 3D fusion imaging in sentinel lymphadenectomy for vilvar cancer. Gynecol Oncol 09 (2008) 76-80
111. Leijte J.A., Valdes Olmos R.A., Nieweg O.E., et al. Anatomical mapping of lymphatic drainage in penile carcinoma with SPECT-CT: Implications for the extent of inguinal lymph node dissection. Eur Urol 54 (2008) 885-890
112. Ganswindt U., Paulsen F., Corvin S., et al. Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition. BMC Cancer 5 (2005) 91
113. Krengli M., Ballare A., Cannillo B., et al. Potential advantage of studying the lymphatic drainage by sentinel node technique and SPECT-CT image fusion for pelvic irradiation of prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) 1100-1104
114. Zaidi H., and Hasegawa B. Determination of the attenuation map in emission tomography. J Nucl Med 44 (2003) 291-315
115. Fricke E., Fricke H., Weise R., et al. Attenuation correction of myocardial SPECT perfusion images with low-dose CT: Evaluation of the method by comparison with perfusion PET. J Nucl Med 46 (2005) 36-744
116. Schulz V., Nickel I., Nömayr A., et al. Effect of CT-based attenuation correction on uptake ratios in skeletal SPECT. Nuklearmedizin 46 (2007) 38-42
117. Römer W., Fiedler E., Pavel M., et al. Attenuation correction of SPECT images based on separately performed CT: Effect on the measurement of regional uptake values. Nuklearmedizin 44 (2005) 20-28
118. 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 32 (2005) 458-469
119. Song H., He B., Prideaux A., et al. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med 47 (2006) 1985-1994
120. Schlemmer H.P., Pichler B.J., Schmand M., et al. Simultaneous MR/PET imaging of the human brain: Feasibility study. Radiology 248 (2008) 1028-1035